Latest News
XPENG Announces Vehicle Delivery Results for May 2026
GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of 32,158 vehicles in May, representing a 4% increas...
2026-06-01 12:47
4264
Millennium Premier Hotel New York Times Square Reopens June 1 Following Comprehensive Renovation
Millennium Hotels and Resorts unveil a reimagined boutique experience in the heart of Manhattan, celebrating the reopening with an exclusive MyMillennium member offer. NEW YORK, June 1, 2026 /PRNewswire/ -- Millennium Hotels and Resorts (MHR), an international hospitality group with over 145 hot...
2026-06-01 12:08
3791
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, todayannounced updated clinical data from its Phase I/II study evaluating ...
2026-06-01 12:00
5450
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi")today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's b...
2026-06-01 11:09
4019
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatoce...
2026-06-01 10:37
5741
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...
2026-06-01 08:15
4004
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...
2026-06-01 08:15
3607
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off o...
2026-06-01 08:00
3601
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...
2026-06-01 08:00
3378
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...
2026-06-01 08:00
3620
New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026
Exploring New Business Opportunities with Global Buyers TAIPEI, May 31, 2026 /PRNewswire/ -- The New Taipei City Government is leading a delegation of 20 companies specializing in smart manufacturing, automation, industrial AI, and key components to participate in AUTOMATE 2026, one of North Ame...
2026-06-01 08:00
2758
United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
LOS ANGELES, May 31, 2026 /PRNewswire/ -- United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, is presenting its latest molecular imaging advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annu...
2026-05-31 23:00
2523
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...
2026-05-31 21:00
3211
Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders
SHANGHAI, May 30, 2026 /PRNewswire/ -- The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards. Held from June 12 to 21, the Festival received approximately 4,100 submissions from 125 countries and regions this ...
2026-05-31 10:33
4324
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...
2026-05-31 08:09
5161
The 7th China-CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week Successfully Held
JINAN, China, May 30, 2026 /PRNewswire/ -- From May 25 to 29, 2026, the 7th China–CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week, hosted by Shandong Provincial People's Government, the Secretariat of Cooperation between China and Centra...
2026-05-30 19:32
4825
Shaping the Future Together! What Global Guests Said at the 2026 China-CEEC Local Leaders' Meeting and Shandong Friendship Cities Week
JINAN, China, May 30, 2026 /PRNewswire/ -- From May 25 to 29, 2026, the 7th China–CEEC Local Leaders' Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week, hosted by Shandong Provincial People's Government, the Secretariat of Cooperation between China and Centra...
2026-05-30 19:28
5029
MakerWorld's First User-Initiated Charity Contest Names Winners, Bringing Global Creators' Goodwill Directly to Cancer Wards
AUGSBURG, Germany, May 30, 2026 /PRNewswire/ -- MakerWorld's first user-initiated charity design contest has completed: winners have now been selected from 2,056 models submitted by 1,008 creators worldwide. Created in support of the Pieksekisten project, the contest drew more than 250,000 unique...
2026-05-30 18:00
4745
Global Times 'Overseas China Week' photo exhibition in Bishkek highlights China-Kyrgyzstan friendship, enhanced SCO cooperation
BEIJING, May 30, 2026 /PRNewswire/ -- The Global Times "Overseas China Week" event landed in Bishkek, capital of Kyrgyzstan on Wednesday, launching the "Linked by Mountains and Rivers, Bound by Shared Hearts - China and Kyrgyzstan Hand-in-Hand for the Future" photo exhibition, during the 2026 Chi...
2026-05-30 13:51
5446
CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements
HONG KONG, May 29, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the "Notification Letter") from Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2026, indicating th...
2026-05-30 08:16
3840
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16
Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00
Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 286 media titles]
2026-06-08 09:00
HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations
[Picked up by 279 media titles]
2026-06-10 11:13
Most Read
NYSE Content Update: PointFive Raises $60 Million to Redefine Efficiency
2026-06-08 20:55
8723
